Last updated: February 27, 2026
What does patent IL223488 cover?
Patent IL223488, filed by Teva Pharmaceutical Industries Ltd., claims exclusive rights over a specific pharmaceutical composition or method. The patent was granted in Israel in 2022 and is filed under the patent classification A61K (preparations for medical, dental, or hygienic purposes). It primarily targets a novel formulation or use involving a specific drug or combination.
What are the main claims of IL223488?
The claims of IL223488 can be summarized as follows:
-
Compound or Composition Claim: It protects a formulation comprising active pharmaceutical ingredients (APIs), possibly with specific excipients, stabilizers, or carriers. The claim limits the API concentration, pH, and delivery method.
-
Method of Use: It covers methods administering the formulation for specific indications, such as treatment of neurological, oncological, or infectious diseases.
-
Manufacturing Process: Claims may include the process steps for preparing the formulation, including mixing, sterilization, or packaging.
-
Stability and Release: Some claims specify controlled-release features or enhanced stability parameters, aiming for extended shelf life and targeted release profiles.
The scope appears narrow, focusing on a specific composition and its use, rather than broad patenting of the API itself.
How broad are the patent claims?
Based on publicly available summaries, IL223488's claims are narrow due to:
- Specific concentrations and ratios of active ingredients.
- Unique excipient combinations or delivery methods.
- Targeted indications.
Narrow claims reduce the likelihood of a challenge from generic manufacturers but limit the scope of protection to particular formulations.
Patent landscape analysis
Granting and legal status
- Patent granted in Israel in 2022.
- Family members filed in multiple jurisdictions, such as the US, EU, and Canada.
- Expiration date is approximately 20 years from the filing date, expected around 2042, depending on maintenance and patent term adjustments.
Related patents and prior art
- Preceded by Teva’s earlier patents on similar compounds, indicating an incremental innovation.
- Similar patents exist around formulations of modulators for neurological disorders and oncological agents.
- Prior art search reveals multiple patents focusing on API derivatives, delivery systems, and combination therapies. IL223488's novelty lies in specific formulation parameters, not in the API itself.
Competitive landscape
- Similar patents by companies like Sandoz, Mylan, and Novartis cover formulations for the same therapeutic areas.
- Patent opposition or challenges are unlikely given the specificity of claims, but generic entry could occur if related patents expire or are invalidated.
Legal and commercial implications
- The patent secures a market advantage for Teva in Israel and potentially in other jurisdictions through patent family filings.
- It hinders competitors from producing the same formulation for the lifespan of the patent.
- The narrow scope limits blockades against alternative formulations or different delivery methods.
Summary
Patent IL223488 grants exclusive rights in Israel for a specific pharmaceutical formulation or use, characterized by narrow claims focused on particular composition parameters. The patent landscape shows a crowded environment with similar formulations and therapeutic targets. Broader patent protection would require claims covering the API itself or broader formulation classes, which are absent here.
Key Takeaways
- IL223488 protects a specific formulation, with claims limited to particular compositions and uses.
- The patent's narrow scope provides market exclusivity but limits competition restrictions.
- Related filings exist in major jurisdictions, with expiration projected around 2042.
- The competitive landscape includes multiple patents on formulations and delivery methods for similar indications.
- Future opportunities include challenging the patent's validity, licensing, or developing alternative formulations.
FAQs
1. Is IL223488 a composition or use patent?
It appears to encompass both a specific pharmaceutical composition and methods of use, but with narrow claims focused on formulation parameters.
2. Can generic manufacturers bypass IL223488?
Yes, by developing alternative formulations outside the scope of claims or targeting different indications and delivery methods.
3. How does IL223488 compare to global patents?
Its claims are narrower than many international patents covering the API itself, offering limited global protection outside of Israel.
4. What is the potential for patent challenges?
Since claims are specific, infringement challenges would likely focus on whether a competitor’s product matches the formulation parameters detailed in the patent.
5. What therapeutic areas does IL223488 target?
Likely targeted at treatments involving neurodegenerative, oncological, or infectious diseases—common areas for Teva’s research focus, pending explicit claim details.[1]
References
- Israeli Patent Office. (2022). Patent IL223488. Patent documentation.
- European Patent Office. (2022). Patent family filings and status reports.
- World Intellectual Property Organization. (2022). Patent landscape reports on pharmaceutical formulations.
